TFA Therapeutics, Inc. (RAJAF) stock
Close on Oct 16, 2026Market cap –P/E –Yield –
TFA Therapeutics, Inc. saw revenue fall 0.6% to $1.25M over fiscal 2025.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Dec 31, 2025
Valuation
- Market cap
- –
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $1.25M
- Net income
- -$154.82K
- EPS, diluted
- $0.00
Trading
- Previous close
- $9.18
- Open
- $9.18
- Day's range
- $9.18 – $9.18
- Volume
- 0
Market cap history
Month-end market cap since 2024, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 16, 2026. The S&P 500 is measured by the SPY fund.
| Period | RAJAF | S&P 500 | Difference | RAJAF per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | 0.0% | +1.5% | −1.5 pts | ||
| 3 months | 0.0% | +1.9% | −1.9 pts | ||
| Year to date | 0.0% | +12.8% | −12.8 pts | ||
| 1 year | 0.0% | +16.8% | −16.8 pts |
Six years at a glance
Fiscal years 2020 to 2025, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases TFA Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
About TFA Therapeutics
Medicinal Chemicals & Botanical Products
Cordyceps Sunshine Biotech Holdings Co., Ltd. is a biotechnology company that develops, produces, and markets health and dietary supplement products. The company focuses primarily on the cultivation and deep processing of Cattle camphor mushroom, also known as Antrodia Cinnamomum, as well as Cordyceps fungi. Its product offerings include Chinese medicinal material products and dietary supplements marketed under the brand name Kasaer. The company supplies its products to third-party and related-party distributors and retailers, who in turn serve individual consumers.
Company profile, executives and historyTFA Therapeutics stock: common questions
What is TFA Therapeutics's stock price?
RAJAF closed at $9.18 on Oct 16, 2026, up 0.00% on the day.
What is RAJAF's P/E ratio?
TFA Therapeutics lost money over fiscal 2025 (diluted EPS $0.00), so it has no meaningful P/E ratio.
How much revenue does TFA Therapeutics make?
TFA Therapeutics reported revenue of $1.25M for fiscal 2025, down 0.6% from a year earlier.
Does TFA Therapeutics pay a dividend?
No. TFA Therapeutics has not paid a cash dividend over the last twelve months.
How has RAJAF stock performed over the past year?
Including dividends, RAJAF returned 0.0% over the past year, against +16.8% for the S&P 500.
Who are TFA Therapeutics's competitors?
Companies most similar to TFA Therapeutics by business, industry and size include ADIA, SXTC, CFOO, HYEX, SXTP.
See a number that looks wrong?